PMC:4693303 / 23307-24568
Annnotations
{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/4693303","sourcedb":"PMC","sourceid":"4693303","source_url":"https://www.ncbi.nlm.nih.gov/pmc/4693303","text":"PHARMACEUTICAL AND THERAPEUTIC DEVELOPMENTS\nThe research focused on the pharmaceutical treatment of Ebola infection has produced somewhat disappointing results. One candidate drug, TKM-Ebola, after showing promise in primates, has subsequently been demonstrated to be ineffective in treating human Ebola infection.[54] Although the other experimental IgG-based monoclonal antibody-based drug ZMapp has shown good efficacy in primates,[55] there is no compelling evidence that it is effective in humans.[56] In addition, despite a poorly defined safety profile, the drug recently received fast track approval by the Food and Drug Administration (FDA).[57]\nA number of so-called “small-molecule” agents have been tried during the 2014-2015 Ebola outbreak, including Lamivudine (a nucleoside analog of cytidine by GlaxoSmithKline, UK); Favipiravir (a pyrazinecarboxamide derivative by Toyama Chemical, Japan); and Brincidofovir (a lipid-conjugated analog of cidofovir by Chimerix, USA).[56] Following review by the WHO, lamivudine was not recommended in the management of EBOV disease.[58] The clinical trial of brincidofovir by Chimerix was canceled due to lack of participation in Liberia.[56] There is ongoing clinical trials work (phase II) on favipiravir.[59]","divisions":[{"label":"title","span":{"begin":0,"end":43}},{"label":"p","span":{"begin":44,"end":654}}],"tracks":[{"project":"TEST0","denotations":[{"id":"26752867-235-241-1465724","span":{"begin":503,"end":505},"obj":"[\"25972518\"]"},{"id":"26752867-230-236-1465725","span":{"begin":984,"end":986},"obj":"[\"25972518\"]"},{"id":"26752867-107-113-1465726","span":{"begin":1189,"end":1191},"obj":"[\"25972518\"]"}],"attributes":[{"subj":"26752867-235-241-1465724","pred":"source","obj":"TEST0"},{"subj":"26752867-230-236-1465725","pred":"source","obj":"TEST0"},{"subj":"26752867-107-113-1465726","pred":"source","obj":"TEST0"}]},{"project":"2_test","denotations":[{"id":"26752867-25972518-60482790","span":{"begin":503,"end":505},"obj":"25972518"},{"id":"26752867-25972518-60482791","span":{"begin":984,"end":986},"obj":"25972518"},{"id":"26752867-25972518-60482792","span":{"begin":1189,"end":1191},"obj":"25972518"}],"attributes":[{"subj":"26752867-25972518-60482790","pred":"source","obj":"2_test"},{"subj":"26752867-25972518-60482791","pred":"source","obj":"2_test"},{"subj":"26752867-25972518-60482792","pred":"source","obj":"2_test"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"TEST0","color":"#93ecb9","default":true},{"id":"2_test","color":"#ec9f93"}]}]}}